ArticleActa neurologica Belgica2026
Kinetic and inhibitory profiling of serum MMP-9 in acute spinal cord injury: neurochemical links to injury severity and neuroinflammation.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal cord injury (SCI) is a devastating neurological condition characterized by pronounced neuroinflammation and progressive neurodegeneration. Matrix metalloproteinase-9 (MMP-9) has emerged as a crucial regulator of inflammatory cascades, yet its role as a predictive biomarker and enzyme kinetic behaviour persists ambiguous. MMP-9 has recently become a key and seemingly distinct contributor to brain physiology and pathology. The local and time-constrained nature of MMP-9 actions may be the reason why it is so specific, even when it is released into the brain by cells of different types, such as neurons, glia, and leukocytes.
objectivesThe aims of the study were to examine the enzymatic kinetics of MMP-9 in acute spinal cord injury, determine how MMP-9-inhibitor-I inhibits MMP-9, and correlate MMP-9 levels with the severity of injury and neuroinflammatory indicators to explore the inhibitory response of MMP-9 inhibitor-I in vitro and evaluate the potential relevance of MMP-9 as a severity-associated biomarker and experimental inhibitory target in acute SCI.
methodsIn this cross-sectional study, 160 patients with confirmed acute SCI were stratified according to the American Spinal Injury Association Impairment Scale into Mild/Moderate and severe groups. Serum concentrations of MMP-9, C-reactive protein (CRP), creatine kinase-BB (CK-BB), and routine biochemical markers were quantified. Multivariable regression analyses were performed to adjust for confounding variables, and receiver operating characteristic (ROC) curve analysis was used to assess the discriminatory performance of MMP-9.
resultsMMP-9 levels were significantly elevated in patients with severe SCI compared with Mild/Moderate injury (p < 0.001) and showed a strong positive correlation with injury severity (r = 0.755, p < 0.001) and positive correlation with CK-BB levels (r = 0.223, p = 0.047). MMP-9 remained independently associated with SCI severity in the adjusted model. ROC analysis demonstrated excellent discriminatory performance (AUC = 0.942; 95% CI: 0.878-1.000). Enzymatic kinetic analysis suggested higher apparent catalytic activity in severe cases, Inhibition studies showed a kinetic pattern consistent with non-competitive inhibition by MMP-9 inhibitor-I.
Indexed as
Identifiers
42570066What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.